Skip to content

Doximity DOCS Share Repurchase Program, Remaining Authorized, Amount

Share Repurchase Program, Remaining Authorized, Amount at other companies

Veeva Systems logo
Veeva SystemsVEEV
McKesson logo
McKessonMCK
Genpact logo
GenpactG

Other financials

Income statement

See full
Revenue$145.4M+5.1%
Gross profit$126.0M+1.7%
Operating income$24.8M-49.0%
Net income$19.1M-69.4%
EPS (diluted)$0.10-67.7%

Balance sheet

See full
Cash & equivalents$219.2M+4.6%
Total debt$10.2M-17.8%
Total equity$950.8M-12.2%
Total assets$1.1B-11.1%

Cash flow

See full
Operating cash flow$109.5M+11.2%
CapEx-
Free cash flow$81.6M-17.1%

Valuation

See full
Market cap$3.75B-60.5%

Profitability

See full
Gross margin89.1%-1.1pp
Operating margin33.3%-6.6pp
Net margin30.4%-8.7pp
FCF margin50.6%+2.7pp

Returns & leverage

See full
Return on equity19.3%-3.2pp
Debt / equity0.0×
Current ratio6.1×-0.9×

Where this comes from

Reported directly by Doximity in its filing.

Tagged under the XBRL concept us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1.

The official record: Doximity’s 10-Q, filed February 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Doximity's share repurchase program, remaining authorized, amount.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Doximity's share repurchase program, remaining authorized, amount?
Doximity (DOCS) reported share repurchase program, remaining authorized, amount of $83M in Q4 2025.
How has Doximity's share repurchase program, remaining authorized, amount changed year-over-year?
Doximity's share repurchase program, remaining authorized, amount decreased by 81.6% year-over-year, from $450.8M to $83M.